|
Composite safety, n (%)
|
40 (40)
|
8 (24.2)
|
19 (55.9)
|
13 (39.4)
|
0.028
|
|
QTc prolongation following drug initiation, n (%)
|
28 (28)
|
4 (12.1)
|
13 (38.2)
|
11 (33.3)
|
0.037
|
|
LFT elevation, n (%)
|
8 (8.0)
|
2 (6.1)
|
3 (8.8)
|
3 (9.1)
|
0.876
|
|
Adverse reaction, n (%)
|
9 (9)
|
2 (6.1)
|
5 (15.2)
|
2 (6.1)
|
0.356
|
|
Change in QTc, milliseconds
|
7.5 ± 42.0
|
− 18.0 ± 37.6
|
20.5 ± 37.8
|
22.6 ± 38.6
|
0.001
|
|
Max QTc, milliseconds
|
464.2 ± 35.1
|
460.0 ± 29.5
|
465.4 ± 33.8
|
467.4 42.2
|
0.739
|
|
Change in ALT, units/L
|
93.2 ± 393.6
|
95.1 ± 440.3
|
105.6 ± 448.5
|
78.5 ± 281.2
|
0.964
|
|
Change in AST, units/L
|
192.4 ± 894.7
|
159.5 ± 717.3
|
259.2 ± 1226.2
|
155.4 ± 629.8
|
0.875
|
|
Duration of inpatient therapy, days
|
12.9 ± 15.3
|
11.9 ± 11.9
|
12.6 ± 10.8
|
14.3 ± 21.5
|
0.809
|
|
Mortality, n (%)
|
48 (48)
|
15 (45.5)
|
16 (47.1)
|
17 (51.5)
|
0.878
|
|
ICU length of stay, days
|
12.7 ± 37.1
|
10.0 ± 15.0
|
11.1 ± 23.2
|
17 ± 58.7
|
0.718
|
|
Hospital length of stay, days
|
32.9 ± 37.4
|
31.8 ± 25.9
|
28.2 ± 19.5
|
38.7 ± 56.7
|
0.515
|
|
30 day readmission, n (%)
|
29 (42)
|
8 (34.78)
|
7 (30.4)
|
14 (60.9)
|
0.077
|
|
Recurrent infection, n (%)
|
9 (14.1%)
|
1 (4.5%)
|
4 (19.1%)
|
4 (19.1%)
|
0.230
|
|
Percent change in immunosuppression dose
|
− 46.1 [− 27.8, − 57.8]
|
− 34.3 [− 4.04, − 46.5]
|
− 48.4 [− 35.1, − 65.9]
|
− 46.4 [− 35.1, − 65.9]
|
0.029
|
